参考文献/References:
［1］ Chen XP, Huang ZY. Surgical treatment of hepatocellular carcinoma in China: surgical techniques, indications, and outcomes［J］. Langenbecks Arch Surg, 2005, 390: 259- 265.
［2］ Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future［J］. Ann Surg, 2011, 253: 453- 469.
［3］ Sun HC, Tang ZY, Ma ZC, et al. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background［J］. J Cancer Res Clin Oncol, 2005, 131: 284- 288.
［4］ Itamoto T, Nakahara H, Amano H, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma［J］. Surgery, 2007, 141: 589- 597.
［5］ Nagasue N, Kohno H, Hayashi T, et al. Repeat hepatectomy for recurrent hepatocellular carcinoma［J］. Br J surg, 1996, 83: 127- 131.
［6］ 孙文兵， 丁雪梅， 高 君， 等． 提升肝细胞癌射频消融疗效的技术性措施：外科视角［J］． 中华肝胆外科杂志， 2011， 17： 534- 538．
［7］ Choi D, Lim HK, Rhim H, et al. Percutaneous radiofrequency ablation for recurrent hepatocellular carcinoma after hepatectomy: long- term results and prognostic factors［J］. Ann Surg Oncol, 2007, 14: 2319- 2329.
［8］ Liang HH, Chen MS, Peng ZW, et al. Percutaneous radiofrequency ablation versus repeat hepatectomy for recurrent hepatocellular carcinoma: a retrospective study［J］. Ann Surg Oncol, 2008, 15: 3484- 3493.
［9］ 任正刚， 干育红， 樊 嘉， 等． 射频毁损术与再手术切除治疗复发性小肝癌对照研究［J］． 中华外科杂志， 2008， 46： 1614- 1616．
［10］ Ruzzenente A, Manzoni GD, Molfetta M, et al. Rapid progression of hepatocellular carcinoma after radiofrequency ablation［J］. World J Gastroenterol, 2004, 10: 1137- 1140.
［11］ Hildebrand P, Kleemann M, Roblick UJ, et al. Radiofrequency- ablation of unresectable primary and secondary liver tumors: results in 88 patients［J］. Langenbecks Arch Surg, 2006, 391: 118- 123.
［12］ 梁惠宏， 薛 平， 陈敏山， 等． 经皮射频消融治疗复发性肝癌的预后分析［J］． 中华外科杂志， 2010， 48： 738- 742．
［13］ Lee DH, Lee JM, Lee JY, et al. Radiofrequency ablation for intrahepatic recurrent hepatocellular carcinoma: long- term results and prognostic factors in 168 patients with cirrhosis［J］. Cardiovasc Intervent Radiol, 2014, 37: 705- 715.
［14］ Valls C, Ramos E, Leiva D, et al. Safety and efficacy of ultrasound- guided radiofrequency ablation of recurrent colorectal cancer liver metastases after hepatectomy［J］. Scand J Surg, 2015, 104: 169- 175.
［15］ 陈敏华， 严 昆， 杨 薇， 等． 射频消融治疗方案对肝大肿瘤的临床应用价值［J］． 中华超声影像学杂志， 2004， 13： 190-194．
［16］ Yamashiki N, Yoshida H, Tateishi R, et al. Recurrent hepatocellular carcinoma has an increased risk of subsequent recurrence after curative treatment［J］. J Gastroenterol Hepatol, 2007, 22: 2155- 2160.
［17］ Poon RT, Fan ST, Ng IO, et al. Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma［J］. Cancer, 2000, 89: 500- 507.
［18］ Imamura H, Matsuyama Y, Tanaka E, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy［J］. J Hepatol, 2003, 38: 200- 207.
［19］ 杨 薇， 陈敏华， 严 昆， 等． 射频消融治疗复发性肝细胞癌疗效分析［J］． 中华外科杂志， 2005， 43： 980- 984．
［20］ Witjes CD, Polak WG, Verhoef C, et al. Increased alpha- fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non- cirrhotic livers［J］. Dig Surg, 2012, 29: 522- 528.
［21］ Kim YS, Rhim H, Cho OK, et al. Intrahepatic recurrence after percutaneous radiofrequency ablation of hepatocellular carcinoma: analysis of the pattern and risk factors［J］. Eur J Radiol, 2006, 59: 432- 441.
［22］ Toro A, Ardiri A, Mannino M, et al. Effect of pre- and post- treatment α- fetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study［J］. BMC Surgery 2014, 14: 40.
［23］ 朱 宇， 田银生， 葛明刚． 经肝动脉插管化疗栓塞术联合射频消融术对比射频消融术治疗复发性肝癌的临床研究［J］． 临床外科杂志， 2014， 22： 163- 166．
［24］ Khan KN, Yatsuhashi H, Yamasaki K, et al. Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection［J］. J Hepatol, 2000, 32: 269- 278.
［25］ 骆惊涛， 魏 玺， 周洪渊， 等． 肝癌射频消融术后肝内远处复发的相关因素分析［J］． 中华外科杂志， 2009， 47： 1529- 1531．
［26］ 马志敏， 冯懿正， 周杏仁， 等． 从小肝癌的复发探讨合理的手术方式［J］． 中华外科杂志， 1994， 32： 31- 34．
［27］ Maruyama H, Takahashi M, Shimada T, et al. Pretreatment microbubble- induced enhancement in hepatocellular carcinoma predicts intrahepatic distant recurrence after radiofrequency ablation［J］. AJR Am J Roentgenol, 2013, 200: 570- 577.
［28］ 盛若凡， 任正刚， 张 岚， 等． 小肝癌射频消融治疗前后磁共振成像表现及其与肿瘤肝内复发的相关性［J］． 中华肝脏病杂志， 2014， 22： 680- 685．
［29］ Yang W, Chen MH, Wang MQ, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization in recurrent hepatocellular carcinoma after hepatectomy compared with single treatment［J］. Hepatol Res, 2009, 39: 231- 240.
［30］ 徐 立， 黎 鹏， 陈敏山， 等． 以射频消融为主的微创方式治疗肝癌术后复发［J］． 中华外科杂志， 2008， 46： 1617- 1620．
［31］ 严 昆， 陈敏华， 李荣杰， 等． 残留复发性肝肿瘤射频消融治疗-超声造影的应用价值［J］． 介入放射学杂志， 2014， 23： 496- 499．
相似文献/References:
[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(10):177.
[2]李麟荪.积极开展非血管性介入放射学[J].介入放射学杂志,2000,(04):193.
[3]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(10):333.
[4]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(10):206.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(10):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(10):974.
[7]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(10):636.
[8]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(10):520.
[9]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(10):769.
[10]姚雪松,闫 东,曾辉英,等. TACE联合索拉非尼治疗不能手术切除肝细胞肝癌50例[J].介入放射学杂志,2013,(05):381.
YAO Xue? song,YAN Dong,ZENG Hui? ying,et al. Ttransarterial chemoembolization combined with sorafenib for inoperable hepatocellular carcinoma： a clinical analysis of 50 cases[J].journal interventional radiology,2013,(10):381.
[11]鹿宁宁,王海燕,张英华,等.BCLC 0～A期肝细胞癌消融术后早期复发转移危险因素分析[J].介入放射学杂志,2019,28(06):556.
LU Ningning,WANG Haiyan,ZHANG Yinghua,et al.Analysis of risk factors for early recurrence or metastasis in patients with BCLC 0- A hepatocellular carcinoma after ablation therapy[J].journal interventional radiology,2019,28(10):556.